This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
5 Aug 2013

Novel Microplate Design Improves Assay Performance

Porvair Sciences has developed the Krystal 2000 microplate range to address performance limiting well-to-well crosstalk inherent in most assay plates.

Incorporating unique individual clear cups molded into either a black or white polypropylene matrix, crosstalk is eliminated and the sensitivity, photometric accuracy and repeatability of your bottom reading absorbance, fluorescence and luminescence measurements markedly improved.

Maintaining industry standard 96-well microplate dimensions the Krystal 2000 range is fully compatible with all commercially available plate readers, robotic sample processors and automated liquid handling systems.

Constructed in ultra-pure grade polystyrene, Krystal 2000 microplates are available in opaque white, solid black and black and white combination formats. For sensitive fluorescence measurements the black plate provides the all-absorbing background needed to minimise background interference. The opaque white plate maximizes reflectivity enabling even weakly emitting luminescence assays to be routinely undertaken. 

In addition to optimized luminescence and fluorescence measurements the unique design offers improved cell binding efficiency and allows the convenience of direct measurements on bottom reading spectrophotometers and inverted microscopes.

To download a technical report that evaluates well-to-well crosstalk in commercially available microplates used for luminescence measurements please visit www.porvair-sciences.com/uploads/Determination_of_well_to_well_crosstalk_in_Luminescence_plates.pdf. For further information on the Krystal 2000 range please contact Porvair Sciences Ltd. on +44 1372 824 290 or [email protected]
 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.